Valuation: Fate Therapeutics, Inc.

Market Cap 349M 305M 281M 258M 490M 33.53B 498M 3.36B 1.32B 16.39B 1.31B 1.28B 56.49B P/E 2026 *
-2.76x
P/E 2027 * -2.9x
Enterprise Value 349M 305M 281M 258M 490M 33.53B 498M 3.36B 1.32B 16.39B 1.31B 1.28B 56.49B EV / Sales 2026 *
66.4x
EV / Sales 2027 * 66.6x
Free-Float
98.83%
Yield 2026 *
-
Yield 2027 * -
1 day-2.84%
1 week-1.54%
Current month+6.85%
1 month+43.53%
3 months+123.64%
6 months+174.76%
Current year+193.61%
1 week 2.8
Extreme 2.8
3.23
1 month 1.81
Extreme 1.8125
3.23
Current year 0.97
Extreme 0.97
3.23
1 year 0.91
Extreme 0.91
3.23
3 years 0.66
Extreme 0.6611
8.83
5 years 0.66
Extreme 0.6611
97.43
10 years 0.66
Extreme 0.6611
121.16
Manager TitleAgeSince
Chief Executive Officer 49 31/12/2024
Director of Finance/CFO 47 19/10/2025
Chief Operating Officer - 30/06/2021
Director TitleAgeSince
Director/Board Member 70 16/03/2014
Chairman 78 30/11/2011
Director/Board Member 47 30/07/2018
Date Insider Type Main position Quantity % Market Cap.
06-11Free

Director

87,900 0.0754%
06-11Free

Director

87,900 0.0754%
06-11Free

Director

175,800 0.1508%
Change 5-day change 1-year change 3-year change Capi.($)
-2.84%-1.54%+155.31%-38.09% 349M
-1.39%-6.15%+56.05%+71.53% 54.49B
+3.13%+11.16%+67.30%+94.35% 55.93B
-0.82%-6.35%+6.09%+427.20% 23.87B
+0.16%-3.35%-18.30%-15.68% 22.86B
+3.51%+7.50%+47.81%-3.33% 20B
+1.94%+0.21%+39.31%-29.41% 17.48B
+10.00%-2.06%+210.10%+370.99% 15.39B
+7.69%+4.38%+56.51%+712.88% 15.19B
-0.35%-0.57%+26.62%+190.72% 14.02B
Average +2.14%+0.20%+64.68%+178.12% 23.96B
Weighted average by Cap. +1.92%+0.47%+53.04%+157.08%

Financials

2026 *2027 *
Net sales 5.25M 4.59M 4.23M 3.89M 7.37M 505M 7.5M 50.52M 19.82M 247M 19.71M 19.27M 851M 5.24M 4.58M 4.22M 3.88M 7.36M 504M 7.48M 50.42M 19.78M 246M 19.66M 19.23M 849M
Net income -133M -116M -107M -98.35M -186M -12.76B -190M -1.28B -501M -6.24B -498M -487M -21.5B -148M -129M -119M -110M -208M -14.24B -211M -1.42B -559M -6.96B -556M -543M -23.98B
Net Debt - -
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
15/07/26 US$2.885 -3.51% 949,082
14/07/26 US$2.990 -0.99% 1,876,259
13/07/26 US$3.020 -2.58% 6,046,416
10/07/26 US$3.100 -0.32% 6,523,782
09/07/26 US$3.110 +6.14% 3,050,950
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2.990USD
Average target price
5.411USD
Spread / Average Target
+80.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FATE Stock